Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

Opioid Dependence Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00292123
• Other study ID #: NIDAIRP 326
• Status: Completed
• Phase: Phase 1
• First received: February 14, 2006
• Last updated: January 11, 2017
• Start date: June 1999
• Est. completion date: August 2006

Study information

• Verified date: December 2007
• Source: National Institute on Drug Abuse (NIDA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary goal of this study is to determine how contingency management can best be combined with standard or high doses of methadone to increase simultaneous abstinence from heroin and cocaine.

Description:

A study of people pmaintained on Methadone using contingency management

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: August 2006
• Est. primary completion date: June 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Opioid dependence; cocaine use

Exclusion Criteria:

• Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cocaine Abuse
• Cocaine-Related Disorders
• Opioid Dependence

Intervention

Drug:
• Methadone

Behavioral:
• Contingency Management

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Drug Abuse (NIDA)

References & Publications (7)

Ghitza UE, Epstein DH, Preston KL. Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addict Behav. 2008 Apr;33(4):593-604. — View Citation

Ghitza UE, Epstein DH, Preston KL. Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav. 2007 May;32(5):938-49. — View Citation

Ghitza UE, Epstein DH, Preston KL. Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend. 2007 Dec 1;91(2-3):169-77. — View Citation

Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL, Preston KL. Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol. 2007 Oct;75(5):765-74. — View Citation

Heinz A, Epstein DH, Preston KL. Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs. 2007 Mar;39(1):41-9. — View Citation

Heinz AJ, Epstein DH, Schroeder JR, Singleton EG, Heishman SJ, Preston KL. Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat. 2006 Dec;31(4):355-64. — View Citation

Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat. 2008 Jul;35(1):78-86. — View Citation